| Market Cap | 314.38M |
| Revenue (ttm) | 245.56M |
| Net Income (ttm) | -9.03M |
| Shares Out | 47.42M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,095,527 |
| Open | 6.94 |
| Previous Close | 6.94 |
| Day's Range | 6.45 - 6.99 |
| 52-Week Range | 3.99 - 15.84 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 12.50 (+88.54%) |
| Earnings Date | Nov 6, 2025 |
About LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company operates through two operating segments: Telehealth and WorkSimpli. The company offers telehealth platform comprising RexMD, a men’s telehealth brand that provides access to virtual medical treatment for a variety of men’s health needs, including erectile dysfunction, premature ejaculation, and hair loss; ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
Financial Performance
In 2024, LifeMD's revenue was $212.45 million, an increase of 39.27% compared to the previous year's $152.55 million. Losses were -$21.99 million, -7.23% less than in 2023.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LFMD stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 88.54% from the latest price.
News
LifeMD (LFMD) Sued for Allegedly Misleading Investors on Growth Guidance According to Hagens Berman
Investors who lost money in LifeMD after its stock plunged 44 percent due to allegedly misleading financial statements are urged to contact Hagens Berman.
LIFEMD DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges LifeMD Investors to Contact the Firm Before the October 27th Deadline
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options If you purchased or acquired...
LFMD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding In LifeMD To Contact Him Directly To Discuss Their Options
LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman
Investors who lost money in LifeMD after its stock plunged 44 percent due to allegedly misleading financial statements are urged to contact Hagens Berman.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
Telehealth firm LifeMD said on Tuesday it would collaborate with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including those who are insured and whose ...
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk...
Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements According to Hagens Berman
Investors who lost money in LifeMD after its stock plunged 44 percent due to allegedly misleading financial statements are urged to contact Hagens Berman.
LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the ROTH 4th Annual Healthcare Oppor...
LifeMD: Set To Ride A Telehealth Tailwind
LifeMD shares nearly halved in price following a missed earnings report, with subscriber retention being a key issue. LifeMD stock trades at a significant discount to HIMS despite similar subscription...
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividen...
Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executi...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options
LifeMD, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seam...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LifeMD, Inc. (LFMD)
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of N...
Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements – Hagens Berman
SAN FRANCISCO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executi...
Shareholders who lost money in shares of LifeMD, Inc. (NASDAQ: LFMD) Should Contact Wolf Haldenstein Immediately
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP is notifying investors about a federal securities class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) (“Life...
Berger Montague PC Investigates Securities Claims Against LifeMD, Inc. (NASDAQ: LFMD)
PHILADELPHIA , Sept. 4, 2025 /PRNewswire/ -- Berger Montague PC , national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on beh...
LifeMD to Participate in Three Investor Conferences During September
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following inv...
LifeMD: The Dip Could Deepen, Valuation More Attractive
LifeMD saw year-over-year revenue growth for its second quarter slow markedly from the comparable figure in the first quarter. Gross profit margins dipped 200 basis points, versus its year-ago period,...
LFMD Investors Have Opportunity to Join LifeMD, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $LFMD--LFMD Investors Have Opportunity to Join LifeMD, Inc. Fraud Investigation with the Schall Law Firm.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
LifeMD, Inc. (NASDAQ:LFMD) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Pa...
LifeMD Reports Second Quarter 2025 Results
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 m...
Medifast Announces Second Quarter 2025 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter...